Inflammatory mediators and signaling pathways

Inflammatory mediators and signaling pathways encompass the diverse array of molecules and biochemical circuits that orchestrate the body's response to injury, infection, and stress. This broad category includes soluble mediators such as cytokines (e.g., Tumor necrosis factor-alpha, Interleukin-1, Interleukin-6), chemokines, and lipid-derived eicosanoids like prostaglandins and leukotrienes (StatPearls, 2023). These mediators activate specific intracellular signaling cascades, most notably the NF-kappaB, JAK/STAT, and MAPK pathways, which regulate the expression of genes involved in immune cell activation, proliferation, and survival (Nature Reviews Drug Discovery, 2017). While acute inflammation is a protective mechanism, chronic dysregulation of these pathways is central to the pathogenesis of autoimmune diseases (e.g., rheumatoid arthritis), chronic obstructive pulmonary disease (COPD), and various cancers (PubMed, 2021). Pharmacological strategies targeting these pathways include monoclonal antibodies that neutralize specific cytokines and small-molecule inhibitors that block kinase activity. However, because these pathways are fundamental to host defense, therapeutic intervention often presents challenges such as increased susceptibility to infections and potential interference with tissue repair processes (NIH, 2022).

Other names

Inflammatory signaling cascadesPro-inflammatory pathwaysMediators of inflammationCytokine signaling pathways

Modulation of inflammatory responses through the inhibition of specific cytokines, enzymes (e.g., COX-2), or intracellular signaling molecules (e.g., JAK/STAT, NF-kappaB).